GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Dividend Yield %

Verici Dx (Verici Dx) Dividend Yield % : 0.00% (As of Apr. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Dividend Yield %?

As of today (2024-04-26), the Trailing Annual Dividend Yield of Verici Dx is 0.00%.

The historical rank and industry rank for Verici Dx's Dividend Yield % or its related term are showing as below:

VRCDF's Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.025
* Ranked among companies with meaningful Dividend Yield % only.

Verici Dx's Dividend Payout Ratio for the six months ended in Jun. 2023 was 0.00.

As of today (2024-04-26), the Forward Dividend Yield % of Verici Dx is 0.00%.

Verici Dx's Dividends per Share for the six months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Verici Dx Dividend Yield % Historical Data

The historical data trend for Verici Dx's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Dividend Yield % Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
Dividend Yield %
- - -

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
Dividend Yield % - - - - -

Competitive Comparison of Verici Dx's Dividend Yield %

For the Diagnostics & Research subindustry, Verici Dx's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Verici Dx's Dividend Yield % falls into.



Verici Dx Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Verici Dx  (OTCPK:VRCDF) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Verici Dx Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Verici Dx's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (Verici Dx) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines